Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Artículo en Chino | MEDLINE | ID: mdl-23855131

RESUMEN

OBJECTIVE: To explore influence of sodium restricted diet and non-sodium restricted diet on plasma rennin (PRA), angiotensin II (All), ALD, renal blood flow (RBF) and subside of ascites in patients with cirrhotic ascites. METHODS: Eighty cases of hepatitis B with cirrhotic ascites were randomly divided into sodium restricted diet group and non-sodium restricted diet group. 39 cases were in non-sodium restricted diet group, taking sodium chloride 6500-8000 mg daily; 41 cases were in sodium restricted diet group, taking sodium chloride 5000 mg daily. Both groups received diuretics furosemide and spironolactone. Blood sodium, urine sodium, PRA, AII, ALD, RBF ascites subsiding were compared after treatment. RESULTS: In non-sodium restricted diet group, blood sodium and urine sodium increased 10 days after treatment compared with those before treatment, and compared with those of sodium restricted diet group 10 days after treatment, P <0. 01. RBF increased compared with that before treatment, and compared with that of sodium restricted diet group 10 days after treatment, P < 0. 01. Renal damage induced by low blood sodium after treatment was less in non-sodium restricted diet group than that in sodium restricted diet group, P <0. 05. Ascites disappearance upon discharge was more in sodium restricted diet group than that in non-sodium restricted diet group, P <0. 01. Time of ascites disappearance was shorter in non-sodium restricted diet group than that in sodium restricted diet group, P < 0. 01. CONCLUSION: Compared with sodium restricted diet, while using diuretics of both groups, non-sodium restricted diet can increase level of blood sodium, thus increasing excretion of urine sodium and diuretic effect. It can also decrease levels of PRA, AII and ALD, increase renal blood flow and prevent renal damage induced by low blood sodium and facilitate subsiding of ascites.


Asunto(s)
Ascitis/dietoterapia , Quimosina/sangre , Diuréticos/administración & dosificación , Cirrosis Hepática/dietoterapia , Circulación Renal/efectos de los fármacos , Sodio en la Dieta/administración & dosificación , Ascitis/sangre , Ascitis/fisiopatología , Ascitis/orina , Dieta Hiposódica/métodos , Femenino , Furosemida/administración & dosificación , Hepatitis B/sangre , Hepatitis B/dietoterapia , Hepatitis B/fisiopatología , Hepatitis B/orina , Humanos , Cirrosis Hepática/sangre , Cirrosis Hepática/fisiopatología , Cirrosis Hepática/orina , Masculino , Persona de Mediana Edad , Sodio/sangre , Sodio/orina , Espironolactona/administración & dosificación
2.
J Int Med Res ; 41(1): 129-37, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23569138

RESUMEN

OBJECTIVES: An open-label, randomized, controlled, single-centre clinical trial to evaluate the effects of low-protein intake, with or without keto acid supplementation, on nutritional status and proteinuria, in patients with hepatitis B virus (HBV) and early stage chronic glomerulonephritis. METHODS: Patients with chronic glomerulonephritis and HBV infection were randomized to receive a low-protein diet (0.6-0.8 g/kg ideal body weight [IBW] per day) either without (LP group) or with (sLP group) keto acid supplementation (0.1 g/kg IBW per day), for 12 months. Nutritional, clinical and safety parameters were recorded. RESULTS: The study included 17 patients (LP group n = 9; sLP group n = 8). Proteinuria and microalbuminuria were significantly lower in the sLP group at 6 and 12 months compared with baseline, and at 12 months compared with the LP group. There were no significant differences in serum creatinine level or estimated glomerular filtration rate. Nutritional parameters (serum albumin and prealbumin) were significantly improved at 12 months, compared with baseline, in the sLP group. CONCLUSIONS: Restriction of dietary protein intake to 0.6-0.8 g/kg IBW per day appears to have an acceptable safety profile. Supplementation with keto acids is associated with decreased urine protein excretion.


Asunto(s)
Dieta con Restricción de Proteínas , Suplementos Dietéticos , Glomerulonefritis/complicaciones , Glomerulonefritis/dietoterapia , Hepatitis B/complicaciones , Hepatitis B/dietoterapia , Cetoácidos/uso terapéutico , Adulto , Enfermedad Crónica , Demografía , Dieta con Restricción de Proteínas/efectos adversos , Femenino , Glomerulonefritis/virología , Hepatitis B/virología , Virus de la Hepatitis B/fisiología , Humanos , Cetoácidos/efectos adversos , Masculino , Persona de Mediana Edad
3.
Int J Cancer ; 115(2): 290-5, 2005 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-15688396

RESUMEN

To determine if the risk of hepatocellular carcinoma (HCC) is reduced by consumption of soya foods, we conducted a case-control study within a cohort of Japanese A-bomb survivors. We compared the prediagnosis consumption of isoflavone-rich miso soup and tofu to HCC risk, adjusting for hepatitis B (HBV) and C (HCV) viral infections, the major HCC risk factors in this population. The study included 176 pathologist-confirmed cases of HCC diagnosed in 1964-1988 and 560 controls who died of diseases other than liver cancer. We examined dietary information collected at least 2 years before diagnosis or death and tissue-based measures of viral hepatitis. Using logistic regression, crude ORs were 0.5 (95% CI 0.29-0.95) and 0.5 (95% CI 0.20-0.99) for high vs. low miso soup and tofu intake, respectively. Adjusting for year of birth, sex, HBV, HCV and other factors, the OR for miso soup was unchanged at 0.5 (95% CI 0.14-1.55), and miso results were similar when ORs were recalculated separately for earlier and later birth cohorts to assess consistency of results. The adjusted OR for tofu was 0.9 (95% CI 0.20-3.51). We also found a statistically significant (p < 0.0001) interaction between sex and HCV, with risk of HCC being substantially higher for women. We conclude that consumption of miso soup and other soya foods may reduce HCC risk.


Asunto(s)
Carcinoma Hepatocelular/dietoterapia , Hepatitis B/dietoterapia , Hepatitis C/dietoterapia , Neoplasias Hepáticas/dietoterapia , Alimentos de Soja , Carcinoma Hepatocelular/epidemiología , Carcinoma Hepatocelular/etiología , Estudios de Casos y Controles , Estudios de Cohortes , Conducta Alimentaria , Hepacivirus/aislamiento & purificación , Hepatitis B/complicaciones , Hepatitis B/epidemiología , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis C/complicaciones , Hepatitis C/epidemiología , Humanos , Japón , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/etiología , Factores de Riesgo
4.
An. sist. sanit. Navar ; 27(supl.2): 17-25, 2004. tab, ilus
Artículo en Es | IBECS | ID: ibc-34533

RESUMEN

El espectro clínico de la infección aguda por el virus de la hepatitis B es muy amplio, con cuadros que van desde una hepatitis anictérica y subclínica a una hepatitis ictérica aguda grave e incluso, en algunos casos, a una hepatitis fulminante. El diagnóstico depende en gran medida del grado de sospecha clínica de la hepatitis, estableciéndose el origen etiológico por el virus B mediante el estudio de marcadores serológicos y/o DNA en sangre. Aunque en la mayor parte de los casos la evolución de la hepatitis aguda por virus B es favorable, con resolución espontánea de la clínica en 48 semanas, no es infrecuente en ciertos casos, sobre todo en la infancia, la progresión a hepatitis crónica. No existe ningún tratamiento específico para la infección aguda por virus B que reduzca su gravedad o prevenga su evolución a hepatitis crónica. Se recomienda, no obstante, el reposo relativo, y la administración de una dieta hipercalórica. En las hepatitis agudas graves debe indicarse ingreso hospitalario; en casos de hepatitis fulminante ingreso en UCI para monitorización intensiva y valoración de trasplante hepático si no se produce mejoría espontánea. En el presente artículo se revisa, de forma breve y esquemática, la clínica, el diagnóstico, el pronóstico y el tratamiento de la infección aguda por el virus de la hepatitis B (AU)


Asunto(s)
Hepatitis B/complicaciones , Hepatitis B/diagnóstico , Infecciones/complicaciones , Infecciones/diagnóstico , Biomarcadores/análisis , Virus de la Hepatitis B/aislamiento & purificación , Virus de la Hepatitis B/patogenicidad , Encefalopatía Hepática/complicaciones , Encefalopatía Hepática/diagnóstico , Dieta , Resina de Colestiramina/administración & dosificación , Resina de Colestiramina/uso terapéutico , Reacción en Cadena de la Polimerasa/métodos , Anticuerpos contra la Hepatitis B/análisis , Anticuerpos contra la Hepatitis B , Encefalopatía Hepática/complicaciones , Encefalopatía Hepática/diagnóstico , Hepatitis B/mortalidad , Hepatitis B/fisiopatología , Hepatitis B/dietoterapia , Nutrición Parenteral/métodos , Nutrición Parenteral , Pronóstico
5.
Vopr Pitan ; (1): 10-3, 1998.
Artículo en Ruso | MEDLINE | ID: mdl-9606859

RESUMEN

Acid mussel hydrolisate MIGI-K LP is a food product, and a medical and prophylactic preparation containing a full set of irreplaceable amino acids (with the exception of thriptophane), essential fatty acids, macro- and microelements. MIGI-K LP can be used as a foot additive which improves the taste and increases the food qualities of the product, and as a medical preparation against some diseases.


Asunto(s)
Bivalvos/metabolismo , Aditivos Alimentarios/aislamiento & purificación , Depuradores de Radicales Libres/aislamiento & purificación , Hidrolisados de Proteína/aislamiento & purificación , Protectores contra Radiación/aislamiento & purificación , Mariscos , Adolescente , Adulto , Anciano , Aminoácidos/análisis , Animales , Niño , Preescolar , Ácidos Grasos/análisis , Enfermedades Gastrointestinales/dietoterapia , Hepatitis B/dietoterapia , Hepatitis C/dietoterapia , Humanos , Lactante , Persona de Mediana Edad , Control de Calidad , Oligoelementos/análisis
6.
Oncogene ; 15(23): 2795-801, 1997 Dec 04.
Artículo en Inglés | MEDLINE | ID: mdl-9419970

RESUMEN

Persistent infection with hepatitis B virus (HBV) is one of the primary risk factors for human hepatocellular carcinoma (HCC). In a human ecological study, we have shown that, in addition to HBV, animal food consumption also significantly contributes to the variance of HCC. To test the interacting effect of HBV and animal food consumption on the development of HCC, we investigated HBV expression in HBV transgenic mice fed three levels of casein diet. HBV expression in transgenic animals was substantially inhibited when dietary casein was reduced from the traditional level of 22% to the level of 6%. Northern analysis revealed that suppression of HBV was derived from both the upstream albumin promoter and the internal HBV promoter. Immunochemical staining of liver sections indicated that only a few hepatocytes around the central vein expressed viral surface antigen (HBsAg) in the 6% casein animals, whereas virtually all hepatocytes stained positively for HBsAg in the 22% dietary casein animals. Serum HBsAg concentrations at 4 months were increased by 1.6-, 2.1-, and 5.1- fold over baseline for animals fed the 6%, 14%, and 22% casein diets, respectively. Correspondingly, liver injury was much less severe in animals fed 6% casein diet than in those fed 14% and 22% casein diets. These results demonstrate that a low casein diet is a potent suppresser of HBV transgene and HBV-induced liver injury, suggesting that diet management may be a practical means to aid in the control HBV infection.


Asunto(s)
Caseínas/administración & dosificación , Genes Virales , Virus de la Hepatitis B/genética , Hepatitis B/dietoterapia , Hepatitis B/virología , Transgenes , Proteínas Estructurales Virales/genética , Animales , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Genes Virales/efectos de los fármacos , Hepatitis B/patología , Virus de la Hepatitis B/efectos de los fármacos , Factor de Crecimiento de Hepatocito/biosíntesis , Factor de Crecimiento de Hepatocito/genética , Factor I del Crecimiento Similar a la Insulina/biosíntesis , Factor I del Crecimiento Similar a la Insulina/genética , Masculino , Ratones , Ratones Endogámicos C3H , Ratones Transgénicos , Transgenes/efectos de los fármacos
7.
Aliment Pharmacol Ther ; 10(4): 665-8, 1996 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-8853774

RESUMEN

BACKGROUND: Dietary supplementation with essential fatty acids and polyunsaturated lecithin may improve biochemical and histological parameters in liver disease. METHODS: Ten patients with serological and histological evidence of chronic hepatitis B received capsules of the polyunsaturated fatty acid-rich evening primrose oil in a dose of 4 g daily for 12 months, while a matched group received liquid paraffin capsules as a placebo. RESULTS: Compared to the placebo group, the patients receiving evening primrose oil showed no improvement in either biochemical or histological indices of liver damage, or in the rate of loss of circulating e antigen. CONCLUSIONS: Dietary, supplementation with this dose of essential fatty acids is unlikely to be of benefit in chronic hepatitis B.


Asunto(s)
Grasas Insaturadas en la Dieta/uso terapéutico , Ácidos Grasos Esenciales/uso terapéutico , Hepatitis B/dietoterapia , Adulto , Enfermedad Crónica , Femenino , Hepatitis B/inmunología , Hepatitis B/patología , Antígenos de la Hepatitis B/sangre , Humanos , Ácidos Linoleicos , Hígado/patología , Pruebas de Función Hepática , Masculino , Persona de Mediana Edad , Oenothera biennis , Aceites de Plantas , Ácido gammalinolénico
8.
Isr J Med Sci ; 30(4): 263-6, 1994 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-8175326

RESUMEN

A total of 471 Israel Defense Forces (IDF) blood donors identified as hepatitis B virus (HBV) carriers were examined a few months after blood donation. When compared to the general population of IDF blood donors the HBV carriers were older, belonged to certain ethnic groups and were predominantly males. Physical examination revealed minimal findings: 1 (0.3%) had splenomegaly and 5 (1.6%) had hepatomegaly. Fifty-two individuals (11.1%) had elevated liver enzymes. E antigen was present in 3.2% of HBV carriers, 94% had anti-e antibodies and 1.9% had anti-delta antibodies. Of 258 carriers tested for HBV DNA, 29 (11.2%) were positive. Abnormal liver enzymes were significantly associated with the presence of e antigen as well as with the presence of HBV DNA.


Asunto(s)
Portador Sano , Hepatitis B/epidemiología , Adulto , Donantes de Sangre , ADN Viral/sangre , Femenino , Hepatitis B/dietoterapia , Hepatitis B/inmunología , Antígenos de Superficie de la Hepatitis B/sangre , Antígenos e de la Hepatitis B/sangre , Virus de la Hepatitis B/inmunología , Humanos , Israel/epidemiología , Hígado/enzimología , Masculino , Persona de Mediana Edad
10.
Vrach Delo ; (7): 109-12, 1989 Jul.
Artículo en Ruso | MEDLINE | ID: mdl-2800480

RESUMEN

The authors studied the effect of a dry protein mixture on the clinical course and protein and pigmentary metabolism, functional tests of the liver in 223 patients with viral hepatitis. It was found that this mixture favours reduction of the icteric period, more rapid restoration of the liver function and improves prognosis. The dry protein mixture is recommended to be included in dietotherapy of patients with viral hepatitis.


Asunto(s)
Proteínas en la Dieta/uso terapéutico , Hepatitis A/dietoterapia , Hepatitis B/dietoterapia , Adolescente , Adulto , Anciano , Evaluación de Medicamentos , Femenino , Hepatitis A/metabolismo , Hepatitis B/metabolismo , Humanos , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA